First-Line Pembrolizumab Plus Chemotherapy for Advanced Nonsquamous NSCLC

First-Line Pembrolizumab Plus Chemotherapy for Advanced Nonsquamous NSCLC

User Photo
AnnualMeeting2017

3 years
1,105 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
H. Jack West, MD of Swedish Cancer Institute discusses the updated results of the KEYNOTE-021 study for patients with advanced nonsquamous non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract 9094: First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G.
Up Next Autoplay